0      0

Exhibit Hall Presentation <br>Janssen invites you to learn more about a treatment option for patients diagnosed with Multiple Myeloma who are Relapsed/Refractory and have received >=4 prior lines of therapy</br>Janssen Oncology part of the Pharmaceutical Companies of Johnson & Johnson</br>

‐ Nov 11, 2023 3:30pm

Rhonda Hewitt, NP

You must be logged in and own this session in order to post comments.